Arielle Elkrief
Overview
Explore the profile of Arielle Elkrief including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
2440
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barrichello A, Elkrief A, Ricciuti B, Ganta T, Marron T, Wang X, et al.
Clin Lung Cancer
. 2025 Feb;
PMID: 40021433
Background: Non-small cell lung cancer (NSCLC) patients aged ≥80 years [y] are underrepresented in clinical trials. We evaluated whether age correlates with a distinct immunophenotype or impacts outcomes to first-line...
2.
Samaha R, El Sayed R, Alameddine R, Florescu M, Tehfe M, Routy B, et al.
Curr Oncol
. 2025 Feb;
32(2).
PMID: 39996857
Lung cancer remains the leading cause of cancer mortality globally with EGFR mutations representing a significant driver in advanced non-small cell lung cancer (aNSCLC). The timely detection of these mutations...
3.
Rafie E, Zugman M, Pal S, Routy B, Elkrief A
Eur Urol Focus
. 2025 Jan;
10(6):882-885.
PMID: 39890521
Immune checkpoint inhibitors (ICIs) are rapidly transforming the treatment landscape of genitourinary and other immunogenic malignancies. Despite these advances, biomarkers for the prediction of ICI response remain to be established....
4.
Dankner M, Rousselle E, Petrecca S, Fabi F, Nowakowski A, Lazaratos A, et al.
JCO Precis Oncol
. 2025 Jan;
9:e2400199.
PMID: 39869838
Purpose: MAP2K1/MEK1 mutations are potentially actionable drivers in cancer. MAP2K1 mutations have been functionally classified into three groups according to their dependency on upstream RAS/RAF signaling. However, the clinical efficacy...
5.
Gandhi M, Elkrief A, Moore C, Ricciuti B, Alessi J, Richards A, et al.
J Thorac Oncol
. 2025 Jan;
PMID: 39864548
Introduction: Mutations in STK11, KEAP1, and SMARCA4 predispose to inferior immune checkpoint inhibitor (ICI) efficacy in NSCLC, particularly among KRAS-mutant cases. Nevertheless, the frequency, clinicopathologic features, and clinical impact of...
6.
Zucker M, Perry M, Gould S, Elkrief A, Safonov A, Thummalapalli R, et al.
Cell
. 2024 Dec;
188(3):851-867.e17.
PMID: 39701102
The canonical model of tumor suppressor gene (TSG)-mediated oncogenesis posits that loss of both alleles is necessary for inactivation. Here, through allele-specific analysis of sequencing data from 48,179 cancer patients,...
7.
Shang J, Del Valle D, Britton G, Mead K, Rajpal U, Chen-Liaw A, et al.
J Exp Med
. 2024 Dec;
222(1.
PMID: 39666007
Immunotherapy-related colitis (irC) frequently emerges as an immune-related adverse event during immune checkpoint inhibitor therapy and is presumably influenced by the gut microbiota. We longitudinally studied microbiomes from 38 ICI-treated...
8.
Desilets A, Pinheiro G, Belkaid W, Salko O, Malo J, Zarour E, et al.
JTO Clin Res Rep
. 2024 Dec;
5(12):100737.
PMID: 39624249
Introduction: NSCLC is the leading cause of cancer-related mortality. Although immune-checkpoint inhibitors (ICIs) have improved survival in patients with advanced NSCLC, treatment resistance remains a challenge. Cryoactivation, a technique inducing...
9.
Ricciuti B, Elkrief A, Lin J, Zhang J, Alessi J, Lamberti G, et al.
JTO Clin Res Rep
. 2024 Oct;
5(9):100675.
PMID: 39399157
Introduction: Responses to first-line programmed cell death protein 1 inhibition vary among patients with metastatic NSCLC and a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) greater than or equal...
10.
Vaz V, Gandhi M, Ricciuti B, Alessi J, Elkrief A, Ladanyi M, et al.
JCO Precis Oncol
. 2024 Oct;
8:e2400394.
PMID: 39374479
Crizotinib successfully overcomes MET amplification in ROS1-rearranged NSCLC after entrectinib failure.